IgA nephropathy (also called Berger’s disease) is a common form of chronic glomerulonephritis throughout the world and is clinically characterized by microscopic hematuria and/or proteinuria. IgA nephropathy is generally presumed to be IgA immune complex or polymerized IgA-mediated glomerulonephritis (1). IgA may play an important role in the pathogenesis and development of IgA nephropathy. Several investigators reported that serum IgA is significantly increased in patients with the disease (1). Since elevated serum IgA levels are valuable in the diagnosis of this disease, it is important to quantitate precise amounts of serum IgA in patients with various types of chronic glomerulonephritis. In 1997, the international reference preparation, CRM 470 produced by IFCC, was introduced in Japan (2). The new criterion for IgA nephropathy obtained by nephelometric immunoassay based on the international reference preparation CRM 470 was 315 mg/dl (3). The serum IgA levels were internationally standardized based on evidence.

Ishiguro et al (4) reported that the levels of serum IgA and C3 in patients with IgA nephropathy and other glomerular diseases were adjusted by a special formula to those using international standard serum (IFCC/CRM470). The results showed the highest serum IgA/C3 ratio in patients with IgA nephropathy. The serum IgA/C3 ratio appears to gradually increase according to the prognostic grading of this disease (4). Recently, Komatsu et al (5) studied the serum IgA/C3 ratio, using a standard reference material, in 86 patients with IgA nephropathy and in 32 patients with non-IgA nephropathy.

The serum IgA level was significantly higher, while the C3 level was lower in patients with severe IgA nephropathy compared to those with non-IgA nephropathy. Kaplan-Meier analysis of the patients with IgA nephropathy classified according to the mean serum IgA/C3 ratio revealed that the group with high serum IgA/C3 ratios (4.5 and above) had significantly poorer renal outcome since the cumulative renal survival rate at five years was 84.4% vs 100% (6). It appears that measurement of serum IgA to C3 (serum IgA/C3 ratio) may be useful for the prediction of the diagnosis and prognostic grading in patients with IgA nephropathy.

IgA nephropathy is definitely diagnosed by glomerular mesangial deposition of IgA (mainly IgA1) in renal biopsy specimens as determined by immunohistochemistry. The indicative criteria for renal biopsy used in our division are as follows: presence of persistent proteinuria with or without microscopic hematuria, and an almost normal range of renal function. Maeda et al (6) performed an analysis to distinguish between IgA nephropathy and non-IgA nephropathy using four clinical markers: 1) more than five red blood cells in urinary sediments, 2) persistent proteinuria (urinary protein of more than 0.3 g/day), 3) serum IgA levels of more than 315 mg/dl, and 4) a serum IgA/C3 ratio of more than 3.01. It also appears that three or four clinical markers are useful for distinguishing IgA nephropathy from other primary renal diseases. It is postulated that these clinical markers are useful for the diagnosis of IgA nephropathy without renal biopsy.

Yasuhiko TOMINO, MD
Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, 2-2-1 Hongo, Bunkyo-ku, Tokyo 113-8421

References